» Articles » PMID: 38434148

Tailoring Therapeutics Via a Systematic Beneficial Elements Comparison Between Photosynthetic Bacteria-derived OMVs and Extruded Nanovesicles

Overview
Journal Bioact Mater
Date 2024 Mar 4
PMID 38434148
Authors
Affiliations
Soon will be listed here.
Abstract

Photosynthetic bacteria (PSB) has shown significant potential as a drug or drug delivery system owing to their photothermal capabilities and antioxidant properties. Nevertheless, the actualization of their potential is impeded by inherent constraints, including their considerable size, heightened immunogenicity and compromised biosafety. Conquering these obstacles and pursuing more effective solutions remains a top priority. Similar to extracellular vesicles, bacterial outer membrane vesicles (OMVs) have demonstrated a great potential in biomedical applications. OMVs from PSB encapsulate a rich array of bioactive constituents, including proteins, nucleic acids, and lipids inherited from their parent cells. Consequently, they emerge as a promising and practical alternative. Unfortunately, OMVs have suffered from low yield and inconsistent particle sizes. In response, bacteria-derived nanovesicles (BNVs), created through controlled extrusion, adeptly overcome the challenges associated with OMVs. However, the differences, both in composition and subsequent biological effects, between OMVs and BNVs remain enigmatic. In a groundbreaking endeavor, our study meticulously cultivates PSB-derived OMVs and BNVs, dissecting their nuances. Despite minimal differences in morphology and size between PSB-derived OMVs and BNVs, the latter contains a higher concentration of active ingredients and metabolites. Particularly noteworthy is the elevated levels of lysophosphatidylcholine (LPC) found in BNVs, known for its ability to enhance cell proliferation and initiate downstream signaling pathways that promote angiogenesis and epithelialization. Importantly, our results indicate that BNVs can accelerate wound closure more effectively by orchestrating a harmonious balance of cell proliferation and migration within NIH-3T3 cells, while also activating the EGFR/AKT/PI3K pathway. In contrast, OMVs have a pronounced aptitude in anti-cancer efforts, driving macrophages toward the M1 phenotype and promoting the release of inflammatory cytokines. Thus, our findings not only provide a promising methodological framework but also establish a definitive criterion for discerning the optimal application of OMVs and BNVs in addressing a wide range of medical conditions.

Citing Articles

Photosynthetic Bacteria: Light-Responsive Biomaterials for Anti-Tumor Photodynamic Therapy.

Jiang Y Int J Nanomedicine. 2025; 20():465-482.

PMID: 39811429 PMC: 11730521. DOI: 10.2147/IJN.S500314.


Opportunities and challenges of bacterial extracellular vesicles in regenerative medicine.

Guo J, Huang Z, Wang Q, Wang M, Ming Y, Chen W J Nanobiotechnology. 2025; 23(1):4.

PMID: 39754127 PMC: 11697683. DOI: 10.1186/s12951-024-02935-1.


Lipidomic analysis of plant-derived extracellular vesicles for guidance of potential anti-cancer therapy.

Wang F, Li L, Deng J, Ai J, Mo S, Ding D Bioact Mater. 2024; 46:82-96.

PMID: 39737211 PMC: 11683192. DOI: 10.1016/j.bioactmat.2024.12.001.


Extracellular vesicles for cancer therapy: potential, progress, and clinical challenges.

Ren L, Zhang D, Pang L, Liu S Front Bioeng Biotechnol. 2024; 12:1476737.

PMID: 39398642 PMC: 11466826. DOI: 10.3389/fbioe.2024.1476737.

References
1.
Wang X, Hu S, Li J, Zhu D, Wang Z, Cores J . Extruded Mesenchymal Stem Cell Nanovesicles Are Equally Potent to Natural Extracellular Vesicles in Cardiac Repair. ACS Appl Mater Interfaces. 2021; 13(47):55767-55779. DOI: 10.1021/acsami.1c08044. View

2.
Semba R . Perspective: The Potential Role of Circulating Lysophosphatidylcholine in Neuroprotection against Alzheimer Disease. Adv Nutr. 2020; 11(4):760-772. PMC: 7360459. DOI: 10.1093/advances/nmaa024. View

3.
Klarquist J, Janssen E . Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models. Oncoimmunology. 2012; 1(9):1584-1593. PMC: 3525613. DOI: 10.4161/onci.22660. View

4.
Wo J, Lv Z, Sun J, Tang H, Qi N, Ye B . Engineering probiotic-derived outer membrane vesicles as functional vaccine carriers to enhance immunity against SARS-CoV-2. iScience. 2022; 26(1):105772. PMC: 9729586. DOI: 10.1016/j.isci.2022.105772. View

5.
Yan H, Fan M, Liu H, Xiao T, Han D, Che R . Microbial hydrogen "manufactory" for enhanced gas therapy and self-activated immunotherapy via reduced immune escape. J Nanobiotechnology. 2022; 20(1):280. PMC: 9199139. DOI: 10.1186/s12951-022-01440-7. View